

DAFTAR PUSTAKA

- Afifah, A. M. N. *et al.* (2022) 'Risk Factors for Diabetes Mellitus in Indonesia: Analysis Of IFLS Data 2014' *Jurnal Biometrika dan Kependudukan*, 11(2), pp. 165-174.
- Akkus, G. and Sert, M. (2022) 'Diabetic foot ulcers: A devastating complication of diabetes mellitus continues non-stop in spite of new medical treatment modalities', *World Journal of Diabetes*, 13(12), pp. 1106–1121. doi:10.4239/wjd.v13.i12.1106.
- Antar, S.A. *et al.* (2023) 'Diabetes mellitus: Classification, mediators, and complications; a gate to identify potential targets for the development of new effective treatments', *Biomedicine & Pharmacotherapy*, 168, p. 115734. doi:10.1016/j.biopha.2023.115734.
- Amila., Sembiring, E., Sinarsi. (2023) 'Kadar Laktat Dehidrogenase, Prokalsitonin, D-Dimer Dan Lama Rawat Pasien Terkonfirmasi Covid-19', *Jurnal Ilmu Kedokteran dan Kesehatan*, 10(1), pp.1364-1371.
- Ardian, L. J. (2024) 'The Role of Procalcitonin to Determine Infection in Diabetic Foot Ulcer: An Evidence Based Case Report' *Journal of Diverse Medical Research*, 1(4), pp.7-22.
- Babalola, O. *et al.* (2021) 'Are Procalcitonin levels a prognostic tool in hospitalized patients?', *Chest*, 160(4). doi:10.1016/j.chest.2021.07.986.
- Badan Kebijakan dan Pembangunan Kesehatan (2023) *Survei Kesehatan Indonesia 2023*. Jakarta: Kementerian Kesehatan RI.
- Balakrishnan, K.R. *et al.* (2025) 'Diabetic foot attack: Managing severe sepsis in the diabetic patient', *World Journal of Critical Care Medicine*, 14(1). doi:10.5492/wjccm.v14.i1.98419.
- Berbudi, A. *et al.* (2020) 'Type 2 diabetes and its impact on the immune system', *Current Diabetes Reviews*, 16(5), pp. 442–449. doi:10.2174/1573399815666191024085838.
- Boulton, A.J.M dan Whitehouse, R.W. The Diabetic Foot. [Diperbarui 28 Juli 2023]. In: Feingold KR, Ahmed SF, Anawalt B, *et al.*, editors. Endotext [Internet]. South

- Dartmouth (MA): MDText.com, Inc.; 2000-. Available from:
<https://www.ncbi.nlm.nih.gov/books/NBK409609/>
- Center for Disease Control and Prevention (2024) *Symptoms of diabetes, Centers for Disease Control and Prevention*. Available at: <https://www.cdc.gov/diabetes/signs-symptoms/index.html> (Diakses: 08 Februari 2025).
- Chakrabarti, S.K. and Chattopadhyay, D. (2025) ‘The link between immune aging and type 2 diabetes: A review of mechanisms and implications’, *Exploratory Research and Hypothesis in Medicine*, 000(000), pp. 000–000. doi:10.14218/erhm.2025.00018.
- Choe, E.A. *et al.* (2016) ‘The prevalence and clinical significance of low PROCALCITONIN levels among patients with severe sepsis or septic shock in the emergency department’, *Shock*, 46(1), pp. 37–43. doi:10.1097/shk.0000000000000566.
- Cleland, D.A dan Eranki, A.P. Procalcitonin. [Diperbarui 23 April 2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539794/>
- Dahlan, M.S. (2010) *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. 3rd edn. Jakarta: Salemba Medika.
- Da Ros, R. *et al.* (2024) ‘Burden of infected diabetic foot ulcers on hospital admissions and costs in a third-level center’, *Diabetology*, 5(2), pp. 141–150. doi:10.3390/diabetology5020011.
- Darwis, P. *et al.* (2019) ‘Factors Affecting Hospital Length of Stay in Patient with Diabetic Foot Ulcer’, *Jurnal Bedah Indonesia*, 47(2), pp. 9-16.
- DITJEN P2P (2023) *Laporan Kinerja Semester I Tahun 2023*. Jakarta: Direktorat Jenderal Pencegahan dan Pengendalian Penyakit.
- El-Kafrawy, N.A. *et al.* (2020) ‘Procalcitonin as a marker of diabetic foot ulcer infection’, *The Egyptian Journal of Internal Medicine*, 31(4), pp. 652–657. doi:10.4103/ejim.ejim_29_19.
- El-Sayed, N.A. *et al.* (2023) ‘2. diagnosis and classification of diabetes: *standards of care in diabetes—2024*’, *Diabetes Care*, 47(Supplement_1). doi:10.2337/dc24-s002.

- Farmaki, P. *et al.* (2020) ‘Complication of The Type 2 Diabetes Melitus’ *Perspective: Current Cardiology Reviews*, 16(4), pp. 249-251.
- Galicia-Garcia, U. *et al.* (2020) ‘Pathophysiology of type 2 diabetes mellitus’, *International Journal of Molecular Sciences*, 21(17), p. 6275. doi:10.3390/ijms21176275.
- Gómez-Pimienta, E. *et al.* (2019) ‘Decreased quality of life in individuals with type 2 diabetes mellitus is associated with emotional distress’, *International Journal of Environmental Research and Public Health*, 16(15), p. 2652. doi:10.3390/ijerph16152652.
- Hidayat, B. *et al.* (2022) ‘Direct medical cost of type 2 diabetes mellitus and its associated complications in Indonesia’, *Value in Health Regional Issues*, 28, pp. 82–89. doi:10.1016/j.vhri.2021.04.006.
- Himanshu, D., Ali, W. and Wamique, M. (2020) ‘Type 2 diabetes mellitus: Pathogenesis and genetic diagnosis’, *Journal of Diabetes & Metabolic Disorders*, 19(2), pp. 1959–1966. doi:10.1007/s40200-020-00641-x.
- International Diabetes Federation (2024) *Diabetes facts and figures*. Available at: <https://idf.org/about-diabetes/diabetes-facts-figures/> (Diakses: 24 December 2025).
- Jackson, I. *et al.* (2022) ‘Role of procalcitonin as a predictor of clinical outcomes in hospitalized patients with COVID-19’, *International Journal of Infectious Diseases*, 119, pp. 47–52. doi:10.1016/j.ijid.2022.03.044.
- Kementerian Kesehatan Republik Indonesia (2018) *Laporan Nasional Riskesdas 2018*. Jakarta: Riskesdas RI.
- Kementeri Kesehatan Republik Indonesia (2020) ‘Pedoman Nasional Pelayanan Kedokteran Tata Laksana Diabetes Melitus Tipe 2 Dewasa, Keputusan Menteri Kesehatan RI Nomor HK.01.07/MENKES/603/2020. Jakarta: Kemenkes RI.
- Kementerian Kesehatan Republik Indonesia. (2023) *Lansia 60+ Tahun*. Available at: <https://ayosehat.kemkes.go.id/kategori-usia/lansia> (Accessed: 15 September 2025).

- Kim, J.H. (2022) ‘Clinical utility of Procalcitonin on antibiotic stewardship: A narrative review’, *Infection & Chemotherapy*, 54(4), p. 610. doi:10.3947/ic.2022.0162.
- Lee, S.-H., Park, S.-Y. dan Choi, C.S. (2022) ‘Insulin resistance: From mechanisms to therapeutic strategies’, *Diabetes & Metabolism Journal*, 46(1), pp. 15–37. doi:10.4093/dmj.2021.0280.
- McDermott, K. *et al.* (2023) ‘Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers’, *Diabetes Care*, 46(1), pp. 209–221. doi:10.2337/dci22-0043.
- Omar, J. *et al.* (2023) *Serum procalcitonin (PCT) – is there a role as an early biomarker in infected diabetic foot ulcer (IDFU) patients?*, *Malaysian Orthopaedic Journal*, 17(2), pp. 62–69. doi:10.5704/MOJ.2307.010.
- PERKENI (2021) *PEDOMAN: Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2021*. Jakarta: PB. PERKENI.
- Sawaya, A.P. *et al.* (2020) ‘Deregulated immune cell recruitment orchestrated by FOXM1 impairs human diabetic wound healing’, *Nature Communications*, 11(1). doi:10.1038/s41467-020-18276-0.
- Simbolon, P. W. dan Ibrahim, H. (2020) ‘Risk Factors that Influence Hospital Length of Stay in Diabetic Foot Ulcer with Negative Pressure Wound Therapy at RS. dr. Cipto Mangunkusumo’ *The New Ropanasuri Journal of Surgery* (5)1. pp. 20-24 DOI: 10.7454/nrjs.v5i1.1069 Available at: <https://scholarhub.ui.ac.id/nrjs/vol5/iss1/6>
- Soyoye, D.O. *et al.* (2021) ‘Diabetes and peripheral artery disease: A Review’, *World Journal of Diabetes*, 12(6), pp. 827–838. doi:10.4239/wjd.v12.i6.827.
- Stone, K. *et al.* (2022) ‘A systematic review of the prediction of hospital length of stay: Towards a unified framework’, *PLOS Digital Health*, 1(4). doi:10.1371/journal.pdig.0000017.
- West, R.M. (2021) ‘Best practice in statistics: The use of Log Transformation’, *Annals of Clinical Biochemistry: International Journal of Laboratory Medicine*, 59(3), pp. 162–165. doi:10.1177/00045632211050531.
- Widhowati, F. I., Fatmawati, A., dan Dewi, F. S. T. (2020) ‘Faktor-Faktor Fungsi Fisik Kualitas Hidup Penderita Diabetes Melitus Tipe 2 Di Kabupaten Sleman,

- Yogyakarta: Analisis Data HDSS Sleman Tahun 2015-2017’, *VISIQUES: Jurnal Kesehatan Fakultas Kesehatan Universitas Dian Nuswantoro*, 19(1), pp. 98-108.
- Wu, S. *et al.* (2019) ‘Elevated serum procalcitonin level in patients with chronic kidney disease without infection: A case-control study’, *Journal of Clinical Laboratory Analysis*, 34(2). doi:10.1002/jcla.23065.
- Yunus, I., Fasih, A. dan Wang, Y. (2018) ‘The use of Procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics’, *PLOS ONE*, 13(11). doi:10.1371/journal.pone.0206527.
- Zhou, K. dan Lansang, MC. Diabetes Mellitus and Infection. [Updated 2024 Jun 30]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK569326/>
- Zhu, J. *et al.* (2024) ‘Diabetic peripheral neuropathy: Pathogenetic mechanisms and treatment’, *Frontiers in Endocrinology*, 14. doi:10.3389/fendo.2023.1265372.